Mesoblast’s Cell Remedy Remedy For Graft Versus Host Illness Will get FDA Approval, Inventory Surges – Mesoblast (NASDAQ:MESO)

On Wednesday, the FDA permitted Mesoblast Restricted’s MESO Ryoncil (remestemcel-L) as the primary mesenchymal stromal cell…